ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,146.86
-0.21%
Dow Jones
38,589.16
-0.15%
Gold vs US Dollar
2,333.015
0.00%
Brent Oil
82.275
0.00%
Bitcoin
66,337.99
0.22%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. PMV Pharmaceuticals Inc (PMVP)

  7. PMV Pharmaceuticals Inc (PMVP) News

PMV Pharmaceuticals (PMVP)

PMV Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PMVP
DateTimeSourceHeadlineSymbolCompany
10/06/202421:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PMVPPMV Pharmaceuticals Inc
07/06/202413:32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PMVPPMV Pharmaceuticals Inc
30/05/202412:00GlobeNewswire Inc.PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in JuneNASDAQ:PMVPPMV Pharmaceuticals Inc
29/05/202412:00Business WireFoundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C ReactivatorNASDAQ:PMVPPMV Pharmaceuticals Inc
29/05/202412:00GlobeNewswire Inc.Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C ReactivatorNASDAQ:PMVPPMV Pharmaceuticals Inc
09/05/202413:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PMVPPMV Pharmaceuticals Inc
09/05/202413:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PMVPPMV Pharmaceuticals Inc
09/05/202413:00GlobeNewswire Inc.PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate HighlightsNASDAQ:PMVPPMV Pharmaceuticals Inc
27/03/202412:00GlobeNewswire Inc.PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid TumorsNASDAQ:PMVPPMV Pharmaceuticals Inc
18/03/202420:01GlobeNewswire Inc.PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s CancerNASDAQ:PMVPPMV Pharmaceuticals Inc
29/02/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PMVPPMV Pharmaceuticals Inc
29/02/202421:01GlobeNewswire Inc.PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate HighlightsNASDAQ:PMVPPMV Pharmaceuticals Inc
26/02/202413:00GlobeNewswire Inc.PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care ConferenceNASDAQ:PMVPPMV Pharmaceuticals Inc
24/01/202414:01Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PMVPPMV Pharmaceuticals Inc
22/01/202421:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PMVPPMV Pharmaceuticals Inc
22/01/202421:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PMVPPMV Pharmaceuticals Inc
18/01/202421:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PMVPPMV Pharmaceuticals Inc
18/01/202421:01GlobeNewswire Inc.PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash RunwayNASDAQ:PMVPPMV Pharmaceuticals Inc
11/01/202421:18Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PMVPPMV Pharmaceuticals Inc
05/01/202421:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PMVPPMV Pharmaceuticals Inc
05/01/202421:01GlobeNewswire Inc.PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage DevelopmentNASDAQ:PMVPPMV Pharmaceuticals Inc
09/11/202313:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PMVPPMV Pharmaceuticals Inc
09/11/202313:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PMVPPMV Pharmaceuticals Inc
09/11/202313:00GlobeNewswire Inc.PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate HighlightsNASDAQ:PMVPPMV Pharmaceuticals Inc
12/10/202322:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PMVPPMV Pharmaceuticals Inc
12/10/202317:30GlobeNewswire Inc.PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C MutationNASDAQ:PMVPPMV Pharmaceuticals Inc
11/10/202321:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PMVPPMV Pharmaceuticals Inc
11/10/202317:00GlobeNewswire Inc.PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL WebinarNASDAQ:PMVPPMV Pharmaceuticals Inc
20/09/202321:05GlobeNewswire Inc.PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsNASDAQ:PMVPPMV Pharmaceuticals Inc
18/09/202321:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PMVPPMV Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:PMVP

Your Recent History

LSE
LLOY
Lloyds Banking
LSE
PANR
Pantheon Resources
LSE
GOLD
LSE
BIRD
Blackbird
LSE
VAST
Vast Resources
LSE
ENET
Ethernity Networks
LSE
ARCM
Arc Minerals
LSE
NSCI
Netscientific
LSE
SBTX
Skinbiotherapeutics
LSE
NEXN
Nexxen
LSE
TERN
Tern
LSE
GNC
Greencore
LSE
AV.
Aviva
LSE
SRSP
Sirius Petroleum
LSE
POS
Plexus
LSE
PHNX
Phoenix
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved